SAN
JOSE, Calif., Feb. 11,
2025 /PRNewswire/ -- Anixa Biosciences, Inc.
("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company
focused on the treatment and prevention of cancer, today announced
that Mike Catelani, President and
CFO of Anixa, will be participating in the 18th Annual European
Life Sciences CEO Forum taking place February 26-27, 2025, at the Hilton Zurich
Airport Hotel in Zurich,
Switzerland.
The conference brings together leading executives, investors,
and industry experts from the global life sciences sector to
discuss the latest innovations, investment trends, and partnership
opportunities. Mr. Catelani will provide an update on Anixa's
pipeline, highlighting its groundbreaking CAR-T therapy for ovarian
cancer in collaboration with Moffitt Cancer Center, its breast
cancer vaccine developed in partnership with Cleveland Clinic, and
its expanding portfolio of cancer vaccine programs aimed at
addressing multiple hard-to-treat cancers.
Presentation Details:
- Event: 18th Annual European Life Sciences CEO
Forum
- Location: Hilton Zurich Airport Hotel
- Date: February 27, 2025
- Time: 10:40 AM CET
The presentation will highlight recent clinical advancements and
strategic initiatives aimed at accelerating the development of
Anixa's innovative therapies. Additionally, Mr. Catelani will
engage in one-on-one meetings with potential partners and
investors.
"We are excited to participate in this prestigious event and
share updates on our cutting-edge programs," said Mike Catelani, President and CFO of Anixa
Biosciences. "As we continue to advance our pipeline, we look
forward to collaborating with investors and industry leaders who
share our dedication to developing innovative and life-changing
oncology therapies."
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-18th-annual-european-life-sciences-ceo-forum-302373037.html
SOURCE Anixa Biosciences, Inc.
